依洛尤单抗对近期心肌梗死患者心血管结局的疗效:FOURIER试验预设二次分析
FOURIER试验预设二次分析纳入22 320例有既往心梗日期的动脉粥样硬化性心血管疾病患者,比较近期心梗(随机化前12个月内)与远期心梗(超过12个月)的心血管事件风险及依洛尤单抗疗效。结果显示,近期心梗患者3年主要终点事件率更高(17.2% vs 14.4%,校正HR 1.45),依洛尤单抗对主要终点和关键次要终点的相对风险降低分别为19%和25%,绝对风险降低更大(3.7% vs 1.1%;3.2% vs 1.3%)。
要点
- 近期心梗患者3年主要终点事件率17.2%,高于远期心梗的14.4%(校正HR 1.45)
- 依洛尤单抗降低近期心梗主要终点风险19%(HR 0.81),关键次要终点25%(HR 0.75)
- 近期心梗患者3年主要终点绝对风险降低3.7%,高于远期心梗的1.1%
核心结论
- 近期心梗患者心血管事件风险更高,依洛尤单抗的绝对风险降低幅度更大,支持对极高危患者积极降低LDL-C。
研究设计与样本
- FOURIER试验预设二次分析,纳入27 564例接受他汀治疗的动脉粥样硬化性心血管疾病患者,随机接受依洛尤单抗或安慰剂。
- 其中22 320例有已知心梗日期,分为近期心梗(随机化前12个月内)和远期心梗(超过12个月)。
- 按方案排除随机化前4周内发生心梗的患者;数据收集于2013年2月至2016年11月,分析于2019年5月至2020年2月。
主要发现
- 近期心梗患者5711例,远期心梗患者16 609例;近期心梗患者更年轻,高强度他汀治疗比例更高(77.3% vs 69.3%)。
- 近期心梗患者中,依洛尤单抗降低主要终点风险19%(HR 0.81;95%CI 0.70-0.93),关键次要终点25%(HR 0.75;95%CI 0.62-0.91)。
关键数值与推荐
- 2018年AHA/ACC多学会胆固醇管理指南将近期(过去12个月内)心梗患者列为极高危。
- 对极高危患者,若LDL-C≥70 mg/dL或非HDL-C≥100 mg/dL,在最大耐受他汀联合依折麦布基础上加用PCSK9抑制剂是合理的。
临床怎么用
- 对近期心梗(12个月内)患者应识别为极高危人群,积极评估LDL-C水平。
- 在最大耐受他汀联合依折麦布基础上,若LDL-C≥70 mg/dL或非HDL-C≥100 mg/dL,可考虑加用依洛尤单抗。
- 近期心梗患者从依洛尤单抗治疗中获得的绝对风险降低更大,支持更强化降脂策略。
局限性
- 为预设二次分析,非主要终点分析,结果需谨慎解读。
- 排除随机化前4周内发生心梗的患者,不能外推至极早期心梗人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol identified patients with recent (past 12 months) myocardial infarction (MI) as very high risk, in whom a PCSK9 inhibitor is reasonable to add to maximally tolerated statin combined with ezetimibe if their low-density lipoprotein cholesterol level is 70 mg/dL or greater or non-high-density lipoprotein cholesterol level is 100 mg/dL or greater. OBJECTIVE: To examine the clinical efficacy of evolocumab in patients with recent MI. DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified secondary analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial, in which 27 564 patients with atherosclerotic cardiovascular disease treated with a statin were randomized to evolocumab vs placebo. Patients with prior MI with a known date (n = 22 320) were stratified as having a recent MI (within 12 months of randomization) or a remote MI (more than 12 months prior to randomization). Per protocol, patients with MI within 4 weeks prior to randomization were excluded from the FOURIER trial. Data were collected from February 2013 to November 2016, and data were analyzed from May 2019 to February 2020. MAIN OUTCOMES AND MEASURES: The primary composite end point was cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary composite end point was cardiovascular death, MI, or stroke. RESULTS: Of 22 320 included patients, 17 516 (78.5%) were male, and the mean (SD) age was 62.2 (9.0) years. Compared with 16 609 patients with a remote MI, 5711 patients with a recent MI were younger and more likely to be treated with high-intensity statin (77.3% [4415] vs 69.3% [11 506]). In the placebo arm, the 3-year Kaplan-Meier rate for the primary end point was 17.2% in patients with recent MI compared with 14.4% in those with remote MI (adjusted HR, 1.45; 95% CI, 1.29-1.64; P < .001). Similarly, the 3-year Kaplan-Meier rates for the key secondary end point was also higher in those with recent MI (10.9% vs 9.5%; adjusted HR, 1.45; 95% CI, 1.24-1.69; P < .001). In patients with a recent MI, evolocumab reduced the risk of the primary and key secondary end points by 19% (hazard ratio [HR], 0.81; 95% CI, 0.70-0.93) and 25% (HR, 0.75; 95% CI, 0.62-0.91), respectively. In patients with a remote MI, evolocumab reduced the risk of the primary and key secondary end points by 8% (HR, 0.92; 95% CI, 0.84-1.01; P for interaction = .13) and 15% (HR, 0.85; 95% CI, 0.76-0.96; P for interaction = .24), respectively. Given the higher event rates in patients with a recent MI, the absolute risk reductions over 3 years with evolocumab were 3.7% in those with recent MI vs 1.1% in those with remote MI for the primary end point and 3.2% vs 1.3%, respectively, for the key secondary end point. CONCLUSIONS AND RELEVANCE: Patients with a recent MI were at higher risk of cardiovascular events and tended to experience greater absolute risk reductions with evolocumab than those with remote MIs. These findings support the concept in US and European guidelines to aggressively lower low-density lipoprotein cholesterol levels in very high-risk patients, such as those with a recent MI. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01764633.
引用
- Gencer B, Mach F, Murphy SA, et al. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial. JAMA Cardiol. 2020. PMID: 32432684. doi:10.1001/jamacardio.2020.0882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。